Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of “Buy” by Brokerages

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has earned an average rating of “Buy” from the eight research firms that are covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.39.

A number of equities analysts have weighed in on VYGR shares. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wedbush restated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group cut their price target on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter valued at about $29,000. Tower Research Capital LLC TRC boosted its stake in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after acquiring an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management grew its holdings in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the period. CWM LLC increased its stake in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after purchasing an additional 9,376 shares in the last quarter. Finally, Oxford Asset Management LLP acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at $60,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

VYGR stock opened at $3.28 on Friday. The business has a fifty day moving average price of $3.22 and a 200 day moving average price of $4.04. Voyager Therapeutics has a fifty-two week low of $2.65 and a fifty-two week high of $9.55. The stock has a market capitalization of $181.52 million, a price-to-earnings ratio of -2.25 and a beta of 0.85.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). Voyager Therapeutics had a negative net margin of 126.49% and a negative return on equity of 27.36%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. On average, equities analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.